<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(3)</volume><submitter>Zhang H</submitter><pubmed_abstract>The interaction between m&lt;sup>6&lt;/sup>A-methylated RNA and chromatin modification remains largely unknown. We found that targeted inhibition of bromodomain-containing protein 4 (BRD4) by siRNA or its inhibitor (JQ1) significantly decreases mRNA m&lt;sup>6&lt;/sup>A levels and suppresses the malignancy of breast cancer (BC) cells &lt;i>via&lt;/i> increased expression of demethylase AlkB homolog 5 (ALKBH5). Mechanistically, inhibition of BRD4 increases the mRNA stability of ALKBH5 &lt;i>via&lt;/i> enhanced binding between its 3' untranslated regions (3'UTRs) with RNA-binding protein RALY. Further, BRD4 serves as a scaffold for ubiquitin enzymes tripartite motif containing-21 (TRIM21) and ALKBH5, resulting in the ubiquitination and degradation of ALKBH5 protein. JQ1-increased ALKBH5 then demethylates mRNA of ex</pubmed_abstract><journal>Acta pharmaceutica Sinica. B</journal><pagination>1552-1570</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12069253</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>BRD4 regulates m&amp;lt;sup&amp;gt;6&amp;lt;/sup&amp;gt;A of ESPL1 mRNA &amp;lt;i&amp;gt;via&amp;lt;/i&amp;gt; interaction with ALKBH5 to modulate breast cancer progression.</pubmed_title><pmcid>PMC12069253</pmcid><pubmed_authors>Peng Y</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Jiang T</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Asadikaram G</pubmed_authors><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Lu L</pubmed_authors><pubmed_authors>Jiang Z</pubmed_authors><pubmed_authors>Xie G</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Yi C</pubmed_authors><pubmed_authors>Zhou D</pubmed_authors><pubmed_authors>Zhong K</pubmed_authors><pubmed_authors>Zhou J</pubmed_authors></additional><is_claimable>false</is_claimable><name>BRD4 regulates m&amp;lt;sup&amp;gt;6&amp;lt;/sup&amp;gt;A of ESPL1 mRNA &amp;lt;i&amp;gt;via&amp;lt;/i&amp;gt; interaction with ALKBH5 to modulate breast cancer progression.</name><description>The interaction between m&lt;sup>6&lt;/sup>A-methylated RNA and chromatin modification remains largely unknown. We found that targeted inhibition of bromodomain-containing protein 4 (BRD4) by siRNA or its inhibitor (JQ1) significantly decreases mRNA m&lt;sup>6&lt;/sup>A levels and suppresses the malignancy of breast cancer (BC) cells &lt;i>via&lt;/i> increased expression of demethylase AlkB homolog 5 (ALKBH5). Mechanistically, inhibition of BRD4 increases the mRNA stability of ALKBH5 &lt;i>via&lt;/i> enhanced binding between its 3' untranslated regions (3'UTRs) with RNA-binding protein RALY. Further, BRD4 serves as a scaffold for ubiquitin enzymes tripartite motif containing-21 (TRIM21) and ALKBH5, resulting in the ubiquitination and degradation of ALKBH5 protein. JQ1-increased ALKBH5 then demethylates mRNA of ex</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-06-01T05:22:53.875Z</modification><creation>2026-04-08T09:35:18.394Z</creation></dates><accession>S-EPMC12069253</accession><cross_references><pubmed>40370540</pubmed><doi>10.1016/j.apsb.2024.12.037</doi></cross_references></HashMap>